

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.weylo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	ATTORNEY DOCKET NO. CONFIRMATION NO.	
10/721,652	11/25/2003	Glenn R. Gibson	8497-US	7110	
74476 Nestle Health	7590 12/22/2009 Pare Nutrition	EXAMINER			
12 Vreeland R	oad, 2nd Floor, Box 697	BARHAM, BETHANY P			
Florham Park,	NJ 07932		ART UNIT	PAPER NUMBER	
			1615		
			NOTIFICATION DATE	DELIVERY MODE	
			12/22/2009	ELECTRONIC	

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdepartment@rd.nestle.com athena.pretory@rd.nestle.com

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/721,652	GIBSON ET AL.	
Examiner	Art Unit	
BETHANY BARHAM	1615	

	BETHANY BARHAM	1615					
The MAILING DATE of this communication appe		orrespondence add	rass				
			7633				
4E REPLY FILED 09 December 2009 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. 3D The reply was filed after a final rejection, but prior bo or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 1.31 or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:							
a) The period for reply expiresmonths from the mailing date of the final rejection.							
b) Mean The period for reply expires on: (1) the mailling date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailling date of the final rejection.							
Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN T MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).							
Extensions of time may be obtained under 37 CFR 1.136(a). The data have been filled is the date for purposes of determining the period of exunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the last forth in (b) above, if checket. Any reply received by the Office are may reduce any earned patient term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL.	on which the petition under 37 CFR 1.1: tension and the corresponding amount of shortened statutory period for reply origing than three months after the mailing date	of the fee. The appropri- nally set in the final Office	ate extension fee te action; or (2) as				
2. The Notice of Appeal was filed on A brief in comp	liance with 37 CFR 41.37 must be t	iled within two month	s of the date of				
filing the Notice of Appeal (37 CFR 41.37(a)), or any exte Notice of Appeal has been filed, any reply must be filed w	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the					
<u>AMENDMENTS</u>							
<ol> <li>The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because         <ul> <li>(a) They raise new issues that would require further consideration and/or search (see NOTE below);</li> </ul> </li> </ol>							
<ul> <li>(b) ☐ They raise the issue of new matter (see NOTE below);</li> <li>(c) ☐ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or</li> </ul>							
(d) They present additional claims without canceling a NOTE: (See 37 CFR 1.116 and 41.33(a)).	corresponding number of finally reje	ected claims.					
4. The amendments are not in compliance with 37 CFR 1.1.	21 See attached Notice of Non-Co	mnliant Amendment (	PTOL-324)				
<ol> <li>Applicant's reply has overcome the following rejection(s)</li> </ol>		inpliant Amendment (	F10L-324).				
Newly proposed or amended claim(s) would be all non-allowable claim(s).		imely filed amendmer	nt canceling the				
7.  For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is profile status of the claim(s) is (or will be) as follows:		l be entered and an e	xplanation of				
Claim(s) allowed: Claim(s) objected to:							
Claim(s) objected to: Claim(s) rejected:							
Claim(s) withdrawn from consideration:							
AFFIDAVIT OR OTHER EVIDENCE							
<ol> <li>The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).</li> </ol>							
<ol> <li>The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessar</li> </ol>	overcome <u>all</u> rejections under appea y and was not earlier presented. Se	and/or appellant fail ee 37 CFR 41.33(d)(1	s to provide a ).				
10. The affidavit or other evidence is entered. An explanatio REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	ntry is below or attach	ed.				
11. 🗵 The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.							
12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s)							
13. Other:							
	(D						
	/K Supervisory Patent Exar	obert A. Wax/					

U.S. Patent and Trademark Office PTOL-303 (Rev. 08-06)

Continuation of 11. does NOT place the application in condition for allowance because: Applicant's arguments are not persausive. The Examiner respectfully suggests that the issues are ripe for appeal by Applicant.

Applicant continues to argue that the Examiner has confused written description with enablement, that a prophetic example of 'about 15 g to about 20 g' FOS and GOS is enough to enable use of the composition with claimed synergistic effect and that the presence of adverse events and teaching away of greater than 10 g of FOS/GOS as taught by the prior art is 'frelevant', since the instant claimed invention results in 'synergistic effects'. Applicant also argues there is burdensome experimentation to 'measur[e] about 15 to about 20 g of flower. The Examiner respectfully points out that while the instant specification does support (is have written description for) the range 'about 15 g to about 20 g' is capable of a person of skill in the art without undue burden, the prior art '124 teaches that such a composition in that amount is not 'useffur' or capable of being 'used' and teaches against such a 'use' since it results in bad side effects at amounts greater than 10 g. The Applicant has not provided factual evidence in the form of a declaration, side-by-side comparison, etc with the clossest prior art to show that the composition is 'useful' at each on the greater than 10 g or that the claimed synergistic effects result at the higher amount of 'about 15 g to about 20 g'. Note enablement is made on the grounds of 'make' and 'use', the rejection of record that is maintained and at issue presently is enablement with respect to 'use'.

Further Applicant argues that the prior ant rejection over Lesen et al in view of Van Leeuwen et al is in directed contrast to the instant caimed invention which requires higher amounts of FOS and GOS of about 15 g to about 20 g' (pg. 10-11 response). The Examiner respectfully points out that the rejection of Lesen et al in view of Van Leeuwen et al is only over claim 27, which does not contain the imitation of about 15 g to about 20 g' FOS and GOS and as such Applicant is arguing limitations of the specification into the claim. Both Lesen et al and Van Leeuwen et al literation of the specification into the claim. Both Lesen et al end Van Leeuwen et al the claim of CS (Lesen et al ox), etc., e